Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice.


Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
01 2019
Historique:
received: 18 10 2017
revised: 27 03 2018
accepted: 12 06 2018
entrez: 22 1 2019
pubmed: 22 1 2019
medline: 15 3 2019
Statut: ppublish

Résumé

The current five-level EQ-5D (EQ-5D-5L) valuation protocol requires the valuation of 86 states. It has been demonstrated that the selection of empirically valued health states affects the extrapolated values in three-level EQ-5D (EQ-3D-3L). In this investigation, we aim to compare the performance of the current EQ-5D-5L valuation design with other designs. 1603 university students participated in a valuation study using a visual analog scale (VAS) to produce values for all EQ-5D-5L states. Different designs were generated to test their prediction accuracy. Subsamples of the dataset were used to mimic data obtained from a particular design; the remaining dataset was used as the validation set. In addition to EuroQol Group Valuation Technology (EQ-VT) design, alternative subsamples and designs were created using random, orthogonal, and "optimizing D-efficiency" sampling methods. The root mean squared error (RMSE) was used as the measure of prediction accuracy. The EuroQol Group Valuation Technology (EQ-VT) design showed an average RMSE of 3.44 on EQ-VAS, for all 3125 health states combined. Notably, a 25-state orthogonal design performed similarly to the EQ-VT design, with a smaller RMSE of 3.40, and was thus the most efficient design. One caveat with respect to the orthogonal design was that it did not predict the mild states well. Our study supports the EQ-VT design. Smaller designs were identified with similar overall prediction accuracy. It is worth investigating whether issues with misprediction of mild states can be resolved, as the use of smaller size designs would reduce the cost of the valuation of EQ-5D-5L considerably.

Identifiants

pubmed: 30661632
pii: S1098-3015(18)32264-2
doi: 10.1016/j.jval.2018.06.015
pii:
doi:

Types de publication

Comparative Study Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

38-44

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Auteurs

Zhihao Yang (Z)

Erasmus University Rotterdam, Rotterdam, The Netherlands; Guizhou Medical University, Guiyang, China. Electronic address: z.yang@erasmusmc.nl.

Nan Luo (N)

National University of Singapore, Singapore, Singapore.

Gouke Bonsel (G)

Erasmus University Rotterdam, Rotterdam, The Netherlands; The EuroQol Office, Rotterdam, The Netherlands.

Jan Busschbach (J)

Erasmus University Rotterdam, Rotterdam, The Netherlands.

Elly Stolk (E)

The EuroQol Office, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH